(Fighting against New Coronary Pneumonia) The Chinese Academy of Sciences team developed new therapeutic antibodies against Coronary Pneumonia and entered clinical trials
China News Agency, Beijing, June 6th (Reporter Sun Zifa) The Institute of Microbiology, Chinese Academy of Sciences released news on the 6th through the official network platform that the clinical trial application of the new human coronavirus monoclonal antibody developed by the anti-epidemic technology research team, It has been officially approved by the State Drug Administration on the 5th, and its Phase I clinical trial will be tested for safety and dosage in healthy people.
This is the world's first clinical trial of a new type of therapeutic antibody against pneumonia in a healthy population after the completion of the non-human primate experiment, marking that the new coronavirus-specific antibody drug with independent intellectual property rights in China has successfully entered the human clinical Evaluation stage.
Since mid-January of this year, the Institute of Microbiology of the Chinese Academy of Sciences has rapidly established a number of anti-epidemic research teams. The team of researchers Yan Jinghua has worked diligently on antibody drugs day and night. After repeated trials and comparisons, two ideal specific antibodies were screened in late February, which have an efficient activity to neutralize the new coronavirus.
The research team used the rhesus monkey new coronavirus infection model to evaluate the effectiveness of the antibody. The results showed that the neutralizing antibody effectively blocked the infection of the new coronavirus, significantly reduced the load of the new coronavirus in the respiratory tract of rhesus monkey, and protected the virus Lung damage caused by infection.
Neutralizing antibodies are a class of specific immunoglobulins that target pathogens and block pathogens from invading cells. They are innovative special drugs developed for new coronavirus. The development of clinical trials of antibody drugs has brought new hope for curbing the spread of new coronavirus. . The research team also reminded that there is still a long way to go from entering the human clinical trial stage to the final use of antibody drugs, and there is still a long way to go in the future.
Previously, the scientific research team of the Institute of Microbiology of the Chinese Academy of Sciences published a major research paper on the new coronavirus online in the international authoritative academic journal Nature in late May, and reported for the first time that it can effectively treat and prevent the new coronavirus in a non-human primate experimental model. Viral infection specific, fully human monoclonal antibody. (Finish)